New York funding
A Humanized Monoclonal Fsh Blocking Antibody For Alzheimer's Disease - Project Summary Alzheimer’s Disease (ad) Stands…
$10.6M
- Funder
- Department of Health and Human Services
- Amount
- $10.6M
- Recipient
- Icahn School Of Medicine At Mount Sinai
- Deadline
- Through August 31, 2027
Purpose
Department of Health and Human Services awarded $10.6M to Icahn School Of Medicine At Mount Sinai for A humanized monoclonal fsh blocking antibody for alzheimer's disease - project summary alzheimer’s disease (ad) stands out as notable in not having a cure among many diseases that affect elderly men and women––in essence, creating an urgent need for a new therapy. it is also unclear why menopausal women have a preponderance of ad, and, while declining estrogen bas been implicated, there is clear clinical correlation with rising levels of follicle stimulating hormone (fsh). we have identified fsh as a target for several aging disorders––osteoporosis, obesity, hypercholesteremia––and now, ad. inhibiting the action of fsh using blocking antibodies reduces body fat, increases bone mass,…
Free account
Create a free account
Track New York funding and save searches across the Network. Free. No card required.
Want to reach the funders and organizations active in your market? Build your Market Network Strategic Plan →
